Ticagrelor for acute coronary syndromes
Sameer Bansilal1, Marc P Bonaca, Marc S Sabatine
1TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Expert Review of Cardiovascular Therapy
|October 24, 2013
Summary
Ticagrelor, a P2Y12 receptor antagonist, significantly reduced cardiovascular death, heart attack, and stroke in acute coronary syndrome patients. This antiplatelet medication offers improved survival rates compared to clopidogrel.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Ticagrelor is a P2Y12 adenosine diphosphate receptor antagonist.
- It offers rapid, consistent, and reversible antiplatelet effects with an acceptable safety profile.
- Existing adenosine diphosphate receptor blockers have limitations in managing acute coronary syndromes.
Purpose of the Study:
- To evaluate the efficacy and safety of ticagrelor compared to clopidogrel.
- To assess ticagrelor's impact on major adverse cardiovascular events and mortality in acute coronary syndrome patients.
Main Methods:
- A large-scale Phase III clinical trial (PLATO) was conducted.
- Patients presenting with acute coronary syndromes were enrolled.
- Ticagrelor was compared against clopidogrel for antiplatelet therapy.
Main Results:
- Ticagrelor significantly reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke.
- Ticagrelor demonstrated significant reductions in both cardiovascular and all-cause mortality.
- The safety profile of ticagrelor was found to be acceptable in the study population.
Conclusions:
- Ticagrelor offers superior outcomes compared to clopidogrel for patients with acute coronary syndromes.
- The drug's favorable impact on mortality signifies a shift in anti-thrombotic therapy.
- Ticagrelor represents a significant advancement in managing acute coronary syndromes.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
502
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
502
01:28Acute Coronary Syndrome IV: Interprofessional Care
528
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
528
01:30Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
961
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
961
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:27Coronary Artery Disease V: Interprofessional Care
452
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452